
Aleksander L Chojecki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8541689/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Optimization of physician and specialty pharmacy clinical workflow in assessment of risk category and symptom burden in patients with myelofibrosis (MF). Leukemia and Lymphoma, 2022, , 1-3.	1.3	0
2	Financial Toxicity Intervention Improves Outcomes in Patients With Hematologic Malignancy. JCO Oncology Practice, 2022, 18, e1494-e1504.	2.9	16
3	Minimal Residual Disease in Acute Myelogenous Leukemia Is Predictive, Unless You Are Over Age 60 and Treated with Decitabine. Transplantation and Cellular Therapy, 2021, 27, 197-198.	1.2	0
4	Iron overload in the HCT patient: a review. Bone Marrow Transplantation, 2021, 56, 1794-1804.	2.4	10
5	Acute Myeloid Leukemia Patients in Complete Remission with Positive Measurable Residual Disease Prior to Allogeneic Transplant Have Worse Outcomes, Similar to Active Disease Regardless of Conditioning Regimen Intensity and Post-Transplant Cyclophosphamide Administration. Blood, 2021, 138. 4907-4907.	1.4	0
6	Financial Toxicity Intervention Improves Quality of Life in Hematologic Malignancy Patients. Blood, 2020, 136, 21-21.	1.4	1
7	Financial Toxicity Intervention Decreases Mortality in High Risk Hematologic Malignancy Patients. Blood, 2020, 136, 14-15.	1.4	2
8	Specialty Pharmacy and Physician Partnership Optimizes Clinical Pathway Adherence in Myelofibrosis (MF): Initial Analysis of a Quality Improvement Initiative. Blood, 2020, 136, 40-41.	1.4	0
9	Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients. Blood, 2020, 136, 5-6.	1.4	0
10	Allogeneic hematopoietic cell transplantation; the current renaissance. Blood Reviews, 2019, 34, 34-44.	5.7	67